Osimertinib—first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?

Saved in:

Bibliographic Details
Published in:	J Thorac Dis
Main Author:	Green, John A.
Format:	Artigo
Language:	Inglês
Published:	AME Publishing Company 2018
Subjects:	Editorial
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC6297465/ https://ncbi.nlm.nih.gov/pubmed/30631492 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2018.09.52
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items